TUBORG BOULEVARD 12, HELLERUP, G7
Announces Positive Opinion from EMA for TransCon CNP in Treatment of Achondroplasia
Grants 35,890 Warrants to Employees
Closing of Warrant Exercise Window
Regains Exclusive Rights to Develop TransCon Technology-Based Products in Metabolic and Cardiovascular Diseases
Announces $400 Million Share Repurchase Program
Announces Week 52 Data from the reACHin Trial Showing Treatment Benefits in Infants with Achondroplasia
Grants 29,380 Warrants to Employees
Enters Binding Term Sheet for Global Settlement and License Agreement with BioMarin Pharmaceutical Inc.
Annual and Transition Report of Foreign Private Issuers
Amended Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Specialized Disclosure Report